Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00620685 · ClinicalTrials.gov registry record · Phase 2
A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate
A Phase 2 study of Arthritis, Rheumatoid, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 7
- Study locations
NCT00620685: Completed Phase 2 study of Arthritis, Rheumatoid, sponsored by Pfizer.
NCT00620685 is a Phase 2 study of Arthritis, Rheumatoid that has completed, run by Pfizer. The registered enrollment target is 27 participants, below the 640-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (96% lower). The trial reports 7 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00620685, a Phase 2 study of Arthritis, Rheumatoid, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 7
- Study locations
Study Summary
The hypothesis of this study is that the p38 inhibitor (PH-797804) will be safe and well tolerated in subjects with rheumatoid arthritis who are taking methotrexate and will not effect the blood levels of methotrexate.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PH-797804
Study Locations (7)
Michigan
- Pfizer Investigational Site - Bingham Farms
- Pfizer Investigational Site - Kalamazoo
Arizona
- Pfizer Investigational Site - Phoenix
Colorado
- Pfizer Investigational Site - Colorado Springs
Florida
- Pfizer Investigational Site - Miami
Maryland
- Pfizer Investigational Site - Frederick
Pennsylvania
- Pfizer Investigational Site - Duncansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
What the finished NCT00620685 record still lists
NCT00620685 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 640-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Arthritis, Rheumatoid appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00620685 lists 7 locations in 6 states (Michigan, Arizona, Colorado).
Frequently Asked Questions
What is clinical trial NCT00620685 about?
NCT00620685 is a clinical study titled "A Study To Evaluate The Safety And Pharmacokinetic Profile Of A P38 Inhibitor (PH-797804) In Subjects With Rheumatoid Arthritis Who Are Also Taking Methotrexate". The hypothesis of this study is that the p38 inhibitor (PH-797804) will be safe and well tolerated in subjects with rheumatoid arthritis who are taking methotrexate and will not effect the blood levels of methotrexate.
What is the current status of trial NCT00620685?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2008-03. Estimated completion is 2008-10.
What conditions does trial NCT00620685 study?
This clinical trial studies the following conditions: Arthritis, Rheumatoid.
What interventions are being tested in trial NCT00620685?
The interventions under investigation include: Placebo (DRUG), PH-797804 (DRUG).
Who is sponsoring clinical trial NCT00620685?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00620685 being conducted?
This trial has 7 study locations across Arizona, Colorado, Florida, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Rheumatoid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00620685's enrollment target sits among peer trials
27 27th of 27 higher than 1 of 27 other Arthritis, Rheumatoid trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Arthritis, Rheumatoid trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
RECRUITING · Phase 2
-
Comparison Of 6 CP-690,550 Doses Vs.Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis
COMPLETED · Phase 2
-
Low Dose Naltrexone for Chronic Pain From Arthritis
COMPLETED · Phase 2
-
Chronic Pain in Rheumatoid Arthritis
RECRUITING
-
R-2487 in Patients With Rheumatoid Arthritis
RECRUITING · Phase 1
-
IMPACT - AndHealth Autoimmune Research Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia